文献速递认知障碍与痴呆

原发性进行性失语症各临床变异型的淀粉样蛋白PET阳性率

Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia.
PubMed 文献 · JAMA Neurol · 2018-01-01

该前瞻性临床-病理病例系列研究纳入89例原发性进行性失语症(PPA)患者,评估各临床变异型的淀粉样蛋白PET阳性率。语义变异型中86%为阴性,非流利/语法障碍变异型中90%为阴性,而logopenic变异型中96%为阳性。混合型PPA中75%为阳性。结论认为logopenic变异型与阿尔茨海默病生物标志物阳性高度相关,而语义和非流利变异型阳性者多提示混合病理。

要点

  • logopenic变异型PPA患者中96%淀粉样蛋白PET阳性,提示阿尔茨海默病病理。
  • 语义变异型和非流利/语法障碍变异型PPA中分别有86%和90%淀粉样蛋白PET阴性。
  • 淀粉样蛋白PET阳性的语义或非流利变异型PPA尸检多显示额颞叶变性合并阿尔茨海默病病理。

核心结论

  • 当前分类下的PPA变异型诊断与阿尔茨海默病生物标志物状态相关,logopenic变异型在超过95%的病例中与碳11标记匹兹堡化合物B阳性相关。
  • 在高度预测额颞叶变性病理的临床综合征中,阿尔茨海默病生物标志物阳性可能更多与混合病理相关而非原发性阿尔茨海默病。

研究设计与样本

  • 前瞻性临床-病理病例系列研究,在一家专注于认知障碍的三级研究诊所进行,患者于2002年1月至2015年12月期间作为前瞻性纵向研究的一部分接受评估。
  • 纳入标准包括临床诊断PPA、完整的言语语言和认知测试、认知评估6个月内完成的磁共振成像以及碳11标记匹兹堡化合物B或氟18标记florbetapir的脑PET扫描结果。
  • 109例因语言症状转诊并接受淀粉样蛋白脑成像的患者中,排除3例语言评估不完整、5例无显著失语、12例初始症状显著超出语言域,最终纳入89例PPA患者。

主要发现

  • 28例为影像支持的语义变异型PPA(11例女性[39.3%];平均[标准差]年龄64[7]岁),31例为非流利/语法障碍变异型PPA(22例女性[71.0%];平均[标准差]年龄68[7]岁),26例为logopenic变异型PPA(17例女性[65.4%];平均[标准差]年龄63[8]岁),4例为混合型PPA。
  • logopenic变异型PPA中25/26例(96%)淀粉样蛋白PET扫描阳性,混合型PPA中3/4例(75%)阳性。
  • 有尸检数据的淀粉样蛋白阳性的语义变异型PPA(4例中2例)和非流利/语法障碍变异型PPA(3例中2例)均诊断为原发性额颞叶变性合并继发性阿尔茨海默病病理;2例淀粉样蛋白PET阳性的logopenic变异型PPA患者尸检证实阿尔茨海默病。
  • 1例淀粉样蛋白PET阴性的混合型PPA患者尸检显示Pick病。

临床怎么用

  • 在PPA临床分型基础上,淀粉样蛋白PET可用于鉴别logopenic变异型(高度提示阿尔茨海默病病理)与非阿尔茨海默病病理变异型。
  • 对于语义变异型或非流利/语法障碍变异型PPA,淀粉样蛋白PET阳性应警惕混合病理(额颞叶变性合并阿尔茨海默病)的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The ability to predict the pathology underlying different neurodegenerative syndromes is of critical importance owing to the advent of molecule-specific therapies. OBJECTIVE: To determine the rates of positron emission tomography (PET) amyloid positivity in the main clinical variants of primary progressive aphasia (PPA). DESIGN, SETTING, AND PARTICIPANTS: This prospective clinical-pathologic case series was conducted at a tertiary research clinic specialized in cognitive disorders. Patients were evaluated as part of a prospective, longitudinal research study between January 2002 and December 2015. Inclusion criteria included clinical diagnosis of PPA; availability of complete speech, language, and cognitive testing; magnetic resonance imaging performed within 6 months of the cognitive evaluation; and PET carbon 11-labeled Pittsburgh Compound-B or florbetapir F 18 brain scan results. Of 109 patients referred for evaluation of language symptoms who underwent amyloid brain imaging, 3 were excluded because of incomplete language evaluations, 5 for absence of significant aphasia, and 12 for presenting with significant initial symptoms outside of the language domain, leaving a cohort of 89 patients with PPA. MAIN OUTCOMES AND MEASURES: Clinical, cognitive, neuroimaging, and pathology results. RESULTS: Twenty-eight cases were classified as imaging-supported semantic variant PPA (11 women [39.3%]; mean [SD] age, 64 [7] years), 31 nonfluent/agrammatic variant PPA (22 women [71.0%]; mean [SD] age, 68 [7] years), 26 logopenic variant PPA (17 women [65.4%]; mean [SD] age, 63 [8] years), and 4 mixed PPA cases. Twenty-four of 28 patients with semantic variant PPA (86%) and 28 of 31 patients with nonfluent/agrammatic variant PPA (90%) had negative amyloid PET scan results, while 25 of 26 patients with logopenic variant PPA (96%) and 3 of 4 mixed PPA cases (75%) had positive scan results. The amyloid positive semantic variant PPA and nonfluent/agrammatic variant PPA cases with available autopsy data (2 of 4 and 2 of 3, respectively) all had a primary frontotemporal lobar degeneration and secondary Alzheimer disease pathologic diagnoses, whereas autopsy of 2 patients with amyloid PET-positive logopenic variant PPA confirmed Alzheimer disease. One mixed PPA patient with a negative amyloid PET scan had Pick disease at autopsy. CONCLUSIONS AND RELEVANCE: Primary progressive aphasia variant diagnosis according to the current classification scheme is associated with Alzheimer disease biomarker status, with the logopenic variant being associated with carbon 11-labeled Pittsburgh Compound-B positivity in more than 95% of cases. Furthermore, in the presence of a clinical syndrome highly predictive of frontotemporal lobar degeneration pathology, biomarker positivity for Alzheimer disease may be associated more with mixed pathology rather than primary Alzheimer disease.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Santos-Santos MA, Rabinovici GD, Iaccarino L, et al. Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. JAMA Neurol. 2018. PMID: 29309493. doi:10.1001/jamaneurol.2017.4309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。